NCT03036930View on ClinicalTrials.gov

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

March 4, 2024

Study Completion Date

March 6, 2026

Conditions
Human Papillomavirus InfectionHuman Papillomavirus-Related Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

HPV Self-Collection

Undergo self-collection of vaginal/cervical samples

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given IM

Trial Locations (6)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

35233

University of Alabama at Birmingham Cancer Center, Birmingham

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

90048

Cedars Sinai Medical Center, Los Angeles

94115

UCSF Medical Center-Mount Zion, San Francisco

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH